As a biomarker for ICIs treatment, PD-L1 expression level has been used as an auxiliary diagnosis in selecting immunotherapy options for NSCLC patients (11), but it is not suitable to predict the efficacy of immunotherapy in SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.